Terms and Conditions

This document governs access to and use of the FINOVAX training and mentorship platform ("FINOVAX", "Company", "We", "Us", "Our"). FINOVAX operates as an independent professional training and education platform. These policies are drafted in accordance with Indian laws and international best practices.

By accessing, enrolling, or using FINOVAX services, you confirm that you have read, understood, and agreed to be legally bound by this document and all annexures herein.


1. LEGAL NATURE OF SERVICES

1.1 FINOVAX provides training, education, mentorship, and skill-development services only.

1.2 FINOVAX is not:

  1. An investment scheme or collective investment vehicle
  2. A deposit-taking or lending entity
  3. A financial product or security
  4. A guarantee-based income program

1.3 FINOVAX does not fall under regulated activities of SEBI (India) or any equivalent international regulator.

1.4 No employment, partnership, agency, fiduciary, or joint venture relationship is created.


2. ELIGIBILITY & USER RESPONSIBILITY

2.1 Users must be 18 years or older and legally competent.

2.2 Users are solely responsible for ensuring that participation is lawful in their jurisdiction.

2.3 FINOVAX may request KYC or verification documents to comply with AML/CFT and platform integrity requirements.


3. FEES, PAYMENTS & TAXATION

3.1 FINOVAX charges a one-time training fee of 1,000 USDT, unless otherwise stated in writing.

3.2 Fees are strictly for training access, mentorship, systems, digital content, and administrative services.

3.3 Fees do not represent capital, investment, or refundable deposits.

3.4 Users are responsible for all taxes, duties, and reporting obligations in their jurisdiction.


4. VALUE-BACK PRODUCT BENEFIT

4.1 Eligible users may receive complimentary products equivalent to 2% of the training fee per month, for a maximum of 50 months, subject to compliance.

4.2 The products offered under this benefit may include products manufactured or marketed by DXN, a globally recognized wellness brand with presence in multiple countries and territories.

4.3 Important Clarification:

  1. FINOVAX has no legal, contractual, partnership, agency, or commercial agreement with DXN.
  2. DXN is not associated, affiliated, sponsoring, endorsing, or involved in FINOVAX in any manner.
  3. DXN does not approve, support, or guarantee FINOVAX’s training programs, benefits, or representations.

4.4 Any purchase, sourcing, or distribution of DXN products under this benefit is done independently by FINOVAX or its users at an individual level, as part of FINOVAX’s internal value-back and community-building strategy.

4.5 The inclusion of DXN products is intended solely to promote wellness awareness and community engagement and should not be construed as a joint business activity.

4.6 This benefit:

  1. Is promotional and goodwill-based
  2. Is non-cashable and non-transferable
  3. Cannot be exchanged for fiat or cryptocurrency

4.7 Product availability may vary by geography; equivalent substitutions may apply.


5. EARNINGS & PERFORMANCE DISCLAIMER

5.1 Any income or performance references (including "2× income potential") are illustrative only.

5.2 FINOVAX does not guarantee income, profits, or results.

5.3 Outcomes depend on individual effort, skills, consistency, leadership ability, and market conditions.


6. CONDITIONAL REFUND POLICY (ANNEXURE A SUMMARY)

6.1 FINOVAX may offer a conditional refund of the training fee.

6.2 Refund eligibility requires:

  1. Completion of all training modules
  2. Documented application of strategies
  3. Continuous participation for the defined evaluation period
  4. No policy violations

6.3 Refund decisions are final and at FINOVAX’s sole discretion.


7. MARKETING, PROMOTION & CONDUCT

7.1 Users must not:

  1. Promise guaranteed income or returns
  2. Misrepresent FINOVAX services
  3. Use unauthorized marketing material

7.2 Violations may result in suspension or termination without refund.


8. INTELLECTUAL PROPERTY

All content, systems, materials, trademarks, and branding are the exclusive intellectual property of FINOVAX and protected under Indian and international laws.


9. LIMITATION OF LIABILITY

FINOVAX shall not be liable for indirect, incidental, consequential, or economic losses. Participation is at the sole risk of the user.


10. GOVERNING LAW & DISPUTE RESOLUTION

10.1 Governing Law: India.

10.2 Disputes shall be resolved through arbitration under the Arbitration and Conciliation Act, 1996 (India).

10.3 International users consent to arbitration seated in India or another mutually agreed jurisdiction.